Company intelligence / Profile preview

Immunovo

's-Hertogenbosch, North Brabant, Netherlandscrunchbase.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Immunovo developed a proprietary platform for creating novel immunotherapeutic drugs targeting cancer, using synthetic immunogens and adjuvants. The company secured seed funding and aimed to build a pipeline of highly specific oncology therapeutics. There are no public reports of successful late-stage clinical results or marketed products.

Therapeutic areas: Oncology
Modalities: Synthetic peptide antigensImmunotherapeuticsImmune stimulants/adjuvants
Industry: Biotech

Drug pipeline

1 asset

VEGF-A peptide vaccine

Unknown

Partnerships

Biox Biosciences BVLupus Ventures BV

Beyond the preview

Go deeper on Immunovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunovo.

Explore the full profile